BioNTech SE (BNTX)

Revenue by Product

Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
COVID-19 Vaccine Revenue (Post-FY2023 Reporting)	2.43B
COVID-19 Vaccine Revenue (Post-FY2023 Reporting) Growth	-35.59%
Other Sales Revenue (Post-FY2023 Reporting)	319.00M
Other Sales Revenue (Post-FY2023 Reporting) Growth	645.33%
Commercial	-
Commercial Growth	-
Research & Development	-
Research & Development Growth	-
Other Sales Revenue (Pre-FY2024 Reporting)	-
Other Sales Revenue (Pre-FY2024 Reporting) Growth	-
COVID-19 Vaccine Revenue (Pre-FY2024 Reporting)	-
COVID-19 Vaccine Revenue (Pre-FY2024 Reporting) Growth	-